Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Elevance Health Earnings Call: Key Takeaways

New CFO Mark Kaye emphasizes a data-driven strategy focused on the Carelon flywheel and generative AI to sustain long-term earnings growth.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Mgmt ConfidenceHigh confidence in 12% long-term EPS growth target and flywheel execution.
Demand VisibilityServing 47 million members; focus on Medicaid redetermination continuity.
Margin TrendsFocus on bending cost curve via Carelon and transforming operating costs.
Op. LeverageGenerative AI deployment to enhance efficiency and automate tasks across workflows.
Pricing PowerAligning commercial pricing to post-pandemic cost structures in 2024.
Vol vs PriceGrowth driven by Carelon penetration and health benefit membership flywheel.
Segment GrowthCarelon to drive greater proportion of earnings; Medicare Advantage needs optimization.
New ClientsExpanding Carelon services to external employer and health plan members.
Capex & Debt50% free cash flow to M&A/reinvestment; 50% to shareholders.
RegulatoryNavigating Medicaid redeterminations and Medicare Advantage risk model changes.
CommentaryStrategic focus on a 'virtuous flywheel' where health benefits drive Carelon.
New LaunchesBioPlus scaling, advanced home delivery pharmacy, and new Carelon risk offerings.

Growth

Historical 15% EPS CAGR over six years; targeting 12% long-term EPS growth.

Outlook

Targeting at least 12% long-term compound annual growth in adjusted diluted EPS.

Risks

Medicaid redeterminations and Medicare Advantage risk model changes present headwinds to membership and margins.

Source

The company's earnings call, NYSE: ELV, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Elevance Health, Inc.: key numbers

Share price
$446.28Close, Nov 16
Market cap
$96.4B
Shares outstanding
216.06MLatest SEC cover page
Sector
Finance
Industry
Hospital & Medical Service PlansSIC 6324

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Elevance Health, Inc.

All →
4:31 PM ET 8-K
Investor Meeting

Elevance Health Investor Meeting

Elevance Health officers are meeting with investors and analysts to reaffirm the company's full-year 2026 financial guidance. The company continues to expect adjusted shareholders’ earnings of at least $29.00 per diluted share and a benefit expense ratio of 90.2% plus or minus 50 basis points.

4:33 PM ET Form 4
Insider Selling

Elevance Health EVP & Chief Digital Info Ofr Ratnakar Lavu Sells $572K of Stock

Ratnakar Lavu, EVP & Chief Digital Info Ofr, sold 1,300 shares of Elevance Health, Inc. at $440.00 a share, worth $572K in total on Nov 5, 2026. Shares held after the trade: 14,849 (-8.1%).

Value
$572K
Shares
1,300
Price
$440.00
Role
EVP & Chief Digital Info Ofr
Holding change
-8.1%
Trade date
Nov 5, 2026
4:31 PM ET Form 4
Insider Selling

Elevance Health EVP & CFO Mark Kaye Sells $4.66M of Stock

Mark Kaye, EVP & CFO, sold 10,584 shares of Elevance Health, Inc. at $434.00 to $447.19 a share (average $440.13) in 13 transactions, worth $4.66M in total on Oct 22, 2026. Shares held after the trade: 19,919 (-1.4%).

Value
$4.66M
Shares
10,584
Average price
$440.13
Role
EVP & CFO
Holding change
-1.4%
Trade date
Oct 22, 2026
2:15 PM ET 10-Q
Financial Results ▶ Call

Elevance Health Q3 2026 Results: Net Income $1.36B, Up 14.8% YoY

For the nine months ended September 30, 2026, Elevance Health reported total operating revenue of $149.8 billion, a slight increase from $148.3 billion in the prior year period. However, shareholders' net income decreased to $4.59 billion compared to $5.12 billion in 2025, primarily driven by higher operating expenses and a decrease in net income for the nine-month period.

Key figure
Net income $1.36B · +14.8% YoY
6:04 AM ET 8-K
Financial Results

Elevance Health Financial Results

Elevance Health reported Q3 2026 operating revenue of $50.4 billion and raised its full-year 2026 adjusted diluted EPS guidance to at least $29.00. The results were driven by improved operating performance in Medicare Advantage and Individual ACA, alongside growth in CarelonRx product revenue.

Term
Q3 2026

“Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business. We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75. By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders.”

Gail K. Boudreaux, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.